1. A phase I/II study of ixazomib, pomalidomide, and dexamethasone for lenalidomide and proteasome inhibitor refractory multiple myeloma (Alliance A061202). Issue 12 (6th October 2021) Authors: Voorhees, Peter M.; Suman, Vera J.; Tuchman, Sascha A.; Laubach, Jacob P.; Hassoun, Hani; Efebera, Yvonne A.; Mulkey, Flora; Bova‐Solem, Misty; Santo, Katelyn; Carlisle, Destin; McCarthy, Philip L.; Richardson, Paul G. Journal: American journal of hematology Issue: Volume 96:Issue 12(2021) Page Start: 1595 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗